Phase 2 Trial of the CDK4 inhibitor Palbociclib (PD0332991) at 125 mg dose in Well-Differentiated or Dedifferentiated Liposarcoma

IMPORTANCE: Over 90% of well-differentiated/de-differentiated liposarcomas (WD/DDLS) have CDK4 amplification. The selective CDK4/CDK6 inhibitor palbociclib inhibits growth and induces senescence in liposarcoma cell lines and xenografts. Our prior phase 2 study demonstrated that treatment with palboc...

詳細記述

保存先:
書誌詳細
出版年:JAMA Oncol
主要な著者: Dickson, Mark A., Schwartz, Gary K., Keohan, Mary Louise, D’Angelo, Sandra P., Gounder, Mrinal M., Chi, Ping, Antonescu, Cristina R., Landa, Jonathan, Qin, Li-Xuan, Crago, Aimee M., Singer, Samuel, Koff, Andrew, Tap, William D.
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991028/
https://ncbi.nlm.nih.gov/pubmed/27124835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.0264
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料